|
No
|
1
|
2
|
3
|
4
|
Bishop et al. [9]
|
Ryan et al. [10]
|
|---|
|
TTR (%)
|
88.6
|
92.2
|
89.6
|
90.1
|
44.4
|
74.0
|
|
Overall PT-INR, mean ± SD
|
2.01 ± 0.30
|
1.87 ± 0.21
|
1.92 ± 0.22
|
2.47 ± 0.50
|
2.32 ± 0.67
|
–
|
|
Overall warfarin dose, mean ± SD
|
4.49 ± 0.76
|
5.13 ± 0.58
|
3.30 ± 0.34
|
3.24 ± 0.33
|
–
|
–
|
|
Major bleeding events
|
|
GI bleeding events
|
no
|
no
|
no
|
no
|
yes (2/11)
|
no
|
|
LVAD site bleeding events
|
no
|
no
|
no
|
no
|
no
|
no
|
|
Other bleeding events
|
no
|
no
|
no
|
no
|
no
|
no
|
|
All thrombosis events
|
|
Pump thrombosis events
|
no
|
no
|
no
|
no
|
no
|
no
|
|
Other thrombosis events
|
no
|
no
|
no
|
no
|
yesa (1/11)
|
yesb (2/162)
|
|
LVAD-related infections
|
no
|
yes
|
yes
|
no
|
–
|
–
|
|
Heart transplants received
|
no
|
yes
|
no
|
no
|
yes (1/11)
|
–
|
- TTR Time in therapeutic range, PT-INR Prothrombin time-international normalized ratio, GI Gastrointestinal, LVAD Left ventricular assist devices
- aCentral nervous system thrombosis, bDeep vein thrombosis
